Hormone therapyFDA-approvedSecond-line
Erleada
Generic name: apalutamide
How it works
Blocks the action of testosterone on cancer cells, slowing growth.
Cancer types
Prostate Cancer— All patients
Efficacy
Studies show that apalutamide can slow cancer growth and reduce symptoms in around 80% of patients.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Apalutamide and ADT Combination for Prostate Cancer Treatment | Prostate Cancer | phase-3 | — | Source → |
| Testing SX-682 and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Docetaxel with Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Treating Prostate Cancer That Has Recurred After Surgery | Prostate Cancer | phase-3 | — | Source → |
| Study of Prostate Cancer Treatment with Apalutamide or Enzalutamide | Prostate Cancer | phase-3 | — | Source → |
| Testing Apalutamide Alone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Low Dose Apalutamide for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Rare Skin Reaction Found in Prostate Cancer Patient Taking Apalutamide | Prostate Cancer | observational | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | The apalutamide group showed significantly higher CRPC-free probability at 24 months (68.2% vs. 39.8%, p < 0.001) compared to the bicalutamide group. | Source → |
| Prostate Cancer Cells May Resist Apalutamide Treatment | Prostate Cancer | lab-study | — | Source → |
| Apalutamide and PSA Decline in Asian Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Confirmed PSA response rates were higher with apalutamide than placebo: 73.9% versus 33.6% for PSA ≤0.2 ng/mL, 90.1% versus 58.2% for PSA reduction ≥50% [PSA50], and 74.8% versus 25.5% for PSA reduction ≥90% [PSA90]. | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Apalutamide Works Better for Some Prostate Cancer Patients | Prostate Cancer | phase-3 | The adjusted hazard ratio for metastasis-free survival was 0.22 (95% CI, 0.17-0.27) for patients with prior local therapy. | Source → |
| Targeting Mitochondria in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| New Guidelines for Using Apalutamide in Prostate Cancer Treatment | Prostate Cancer | review | Increased metastasis-free survival and overall survival following treatment with apalutamide. | Source → |
| Skin Rash Side Effect Found in Chinese Prostate Cancer Patients on Apalutamide | Prostate Cancer | observational | — | Source → |
| Apalutamide therapy linked to longer survival in men with advanced prostate cancer | Prostate Cancer | phase-3 | Apalutamide plus ADT increased the length of time that participants remained alive compared with placebo plus ADT. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.